Trial Profile

A Double-Blind, Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASM 8 (Primary)
Indications Allergic asthma
Focus Biomarker; Therapeutic Use
Sponsors Syntara Limited

Most Recent Events

04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
29 Sep 2011 Results of this trial are anticipated in the second quarter of 2012, according to a Pharmaxis media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com